Pancreatic cancer – What's next?

Siegel, 2018, Cancer statistics, 2018, CA Cancer J Clin, 10.3322/caac.21442 Maggino, 2017, Recent advantages in pancreatic cancer surgery, Curr Treat Options Gastroenterol, 15, 520, 10.1007/s11938-017-0150-2 Tol, 2014, Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS), Surgery, 156, 591, 10.1016/j.surg.2014.06.016 Giovinazzo, 2016, Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma, Br J Surg, 103, 179, 10.1002/bjs.9969 Zhou, 2012, Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta analysis, World J Surg, 36, 884, 10.1007/s00268-012-1461-z Castleberry, 2012, The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program Database, Ann Surg Oncol, 19, 4068, 10.1245/s10434-012-2585-y Mollberg, 2011, Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis, Ann Surg, 254, 882, 10.1097/SLA.0b013e31823ac299 Hartwig, 2014, Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS), Surgery, 156, 1, 10.1016/j.surg.2014.02.009 De Reuver, 2015, Extended pancreatoduodenectomy as defined by the International Study Group for Pancreatic Surgery is associated with worse survival but not with increased morbidity, Surgery, 158, 183, 10.1016/j.surg.2015.03.015 Chen, 2017, Minimally invasive pancreaticoduodenectomy for periampullary disease: a comprehensive review of literature and meta-analysis of outcomes compared with open surgery, BMC Gastroenterol, 17, 120, 10.1186/s12876-017-0691-9 Pędziwiatr, 2017, Minimally invasive versus open pancreatoduodenectomy-systematic review and meta-analysis, Langenbecks Arch Surg, 402, 841, 10.1007/s00423-017-1583-8 Torphy, 2018, Comparing short-term and oncologic outcomes of minimally invasive versus open pancreaticoduodenectomy across low and high volume centers, Ann Surg, 10.1097/SLA.0000000000002810 Adam, 2015, Minimally invasive versus open pancreaticoduodenectomy for cancer: practice patterns and short-term outcomes among 7061 patients, Ann Surg, 262, 372, 10.1097/SLA.0000000000001055 van Hilst, 2017, Minimally invasive versus open distal pancreatectomy for ductal adenocarcinoma (DIPLOMA): a Pan-European Propensity Score Matched Study, Ann Surg Neuzillet, 2018, Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC), Dig Liver Dis, 10.1016/j.dld.2018.08.008 Oettle, 2013, Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial, JAMA, 310, 1473, 10.1001/jama.2013.279201 Neoptolemos, 2010, Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial, JAMA, 304, 1073, 10.1001/jama.2010.1275 Neoptolemos, 2017, Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial, Lancet, 389, 1011, 10.1016/S0140-6736(16)32409-6 Sinn, 2017, CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial, J Clin Oncol, 35, 3330, 10.1200/JCO.2017.72.6463 Tempero, 2017, Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 15, 1028, 10.6004/jnccn.2017.0131 Khorana, 2017, Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 35, 2324, 10.1200/JCO.2017.72.4948 Ducreux, 2015, Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 26 Groot, 2018, Implications of the pattern of disease recurrence on survival following pancreatectomy for pancreatic ductal adenocarcinoma, Ann Surg Oncol, 25, 2475, 10.1245/s10434-018-6558-7 Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923 Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, 369, 1691, 10.1056/NEJMoa1304369 Hongxuan, 2018, The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis, Sci Rep, 8 Conroy, 2018, Unicancer GI PRODIGE 24/CCTG PA.6 trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas, J Clin Oncol, 36, 10.1200/JCO.2018.36.18_suppl.LBA4001 Neoptolemos, 2004, A randomized clinical trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med, 350, 1200, 10.1056/NEJMoa032295 Klinkenbijl, 1999, Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group, Ann Surg, 230, 776, 10.1097/00000658-199912000-00006 Regine, 2008, Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial, JAMA, 299, 1019, 10.1001/jama.299.9.1019 Safran, 2017, Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma, J Clin Oncol, 35, 4007, 10.1200/JCO.2017.35.15_suppl.4007 Van Tienhoven, 2018, Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): a randomized, controlled, multicenter phase III trial, J Clin Oncol, 36, 10.1200/JCO.2018.36.18_suppl.LBA4002 Hammel, 2018, Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC), J Clin Oncol, 36, 4 Keane, 2014, Systematic review of novel ablative methods in locally advanced pancreatic cancer, World J Gastroenterol, 20, 2267, 10.3748/wjg.v20.i9.2267 Paiella, 2016, Local ablative strategies for ductal pancreatic cancer (radiofrequency ablation, irreversible electroporation): a review, Gastroenterol Res Pract, 2016, 10.1155/2016/4508376 Crinò, 2018, EUS-guided Radiofrequency Ablation (EUS-RFA) of solid pancreatic neoplasm using an 18-gauge needle electrode: feasibility, safety, and technical success, J Gastrointestin Liver Dis, 27, 67, 10.15403/jgld.2014.1121.271.eus D’Onofrio, 2017, Percutaneous radiofrequency ablation of unresectable locally advanced pancreatic cancer: preliminary results, Technol Cancer Res Treat, 16, 285, 10.1177/1533034616649292 Marrocchio, 2018, Nonoperative ablations of pancreatic neoplasms, Surg Clin N Am, 98, 127, 10.1016/j.suc.2017.09.010 Zhang, 2018, Precision immuno-oncology: prospects of individualized immunotheraphy for pancreatic cancer, Cancer, 10, 39, 10.3390/cancers10020039 Shumacher, 2015, Neoantigens in cancer immunotherapy, Science, 348, 69, 10.1126/science.aaa4971 Brahmer, 2012, Safety and activity of anti–PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694 Royal, 2010, Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma, J Immunother, 33, 828, 10.1097/CJI.0b013e3181eec14c Chen, 2013, Oncology meets immunology: the cancerimmunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012 Mellman, 2011, Cancer immunotherapy comes of age, Nature, 480, 480, 10.1038/nature10673 Feig, 2012, The pancreas cancer microenvironment, Clin Cancer Res, 18, 4266, 10.1158/1078-0432.CCR-11-3114 Feig, 2012, The pancreas cancer microenvironment, Clin Cancer Res, 18, 4266, 10.1158/1078-0432.CCR-11-3114 Tsujikawa, 2017, Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis, Cell Rep, 19, 203, 10.1016/j.celrep.2017.03.037 Ino, 2013, Immune cell infiltration as an indicator of the immune microenviroment of pancreatic cancer, Br J Cancer, 108, 914, 10.1038/bjc.2013.32 Hilmi, 2018, Immune therapy in pancreatic ductal adenocarcinoma: where are we now?, World J Gastroenterol, 24, 2137, 10.3748/wjg.v24.i20.2137 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 Patel, 2015, PD-L1 expression as a predictive biomarker in cancer immunotherapy, Mol Cancer Ther, 14, 847, 10.1158/1535-7163.MCT-14-0983 Royal, 2010, Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma, J Immunother, 33, 828, 10.1097/CJI.0b013e3181eec14c Soares, 2015, PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors, J Immunother, 38, 1, 10.1097/CJI.0000000000000062 Rizvi, 2015, Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 Humphris, 2017, Hypermutation in pancreatic cancer, Gastroenterology, 152, 68, 10.1053/j.gastro.2016.09.060 Kohlhapp, 2016, Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy, Clin Cancer Res, 22, 1048, 10.1158/1078-0432.CCR-15-2667 Lutz, 2014, Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy, Oncoimmunology, 3, e962401, 10.4161/21624011.2014.962401 Kouo, 2015, Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells, Cancer Immunol Res, 3, 412, 10.1158/2326-6066.CIR-14-0150 Chu, 2015, Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention, Clin Cancer Res, 21, 1549, 10.1158/1078-0432.CCR-14-1186 Laheru, 2008, Allogenic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation, Clin Cancer Res, 14, 1455, 10.1158/1078-0432.CCR-07-0371 Lutz, 2014, Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation, Cancer Immunol Res, 2, 616, 10.1158/2326-6066.CIR-14-0027 Le, 2015, Safety and survival with GVAX pancreas prime and Listeria Monocytogenes expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer, J Clin Oncol, 33, 1325, 10.1200/JCO.2014.57.4244 Uyttenhove, 2003, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, Nat Med, 9, 1269, 10.1038/nm934 Yong, 2017, CART-T Cell therapy of solid tumors, Immunol Cell Biol, 95, 356, 10.1038/icb.2016.128 DeSelm, 2017, CART-T cell therapy for pancreatic cancer, J Surg. Oncol, 116, 63, 10.1002/jso.24627 Byrne, 2016, CD40 stimulation obviates innate sensors and drives T cell immunity in cancer, Cell Rep, 15, 2719, 10.1016/j.celrep.2016.05.058 Beatty, 2017, Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonist, Expert Rev Anticancer Ther, 17, 175, 10.1080/14737140.2017.1270208 Nywening, 2016, Phase 1b study targeting tumor associated macrophages with CCR2 inhibition plus FOLFIRINOX in locally advanced and borderline resectable pancreatic cancer, Lancet Oncol, 17, 652, 10.1016/S1470-2045(16)00078-4 Jiang, 2016, Targting focal adhesion kinase renders pancreatic cancer responsive to checkpoint immunotherapy, Nat Med, 22, 851, 10.1038/nm.4123 Chouaib, 2017, Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer, Oncogene, 36, 439, 10.1038/onc.2016.225 Rodriguez-Rocha, 2011, Adenoviruses induce autophagy to promote virus raplication and oncolysis, Virologi, 416, 9, 10.1016/j.virol.2011.04.017 Wesseling, 2001, Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors, Gene Ther, 8, 969, 10.1038/sj.gt.3301473 Feig, 2012, The pancreas cancer microenvironment, Clin Cancer Res, 18, 4266, 10.1158/1078-0432.CCR-11-3114 Mahalingam, 2015, The cpmbination of intravenous Reolysin and gemcitabine induces reovirus replication and andoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer, BMC Cancer, 15, 513, 10.1186/s12885-015-1518-0 Kim, 2016, Recent progress in developmant of siRNA delivery vehicles for cancer therapy, Adv Drug Deliv Rev, 104, 61, 10.1016/j.addr.2016.06.011 Deltcheva, 2011, CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III, Nature, 471, 602, 10.1038/nature09886 Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477 Waddel, 2015, Whole genome redefine the mutational landscape of pancreatic cancer, Nature, 518, 495, 10.1038/nature14169 Jamal-Hanjani, 2017, Tracking the evolution of non small cell lung cancer, N Eng J Med, 376, 2109, 10.1056/NEJMoa1616288 Bailey, 2016, Nature, 531, 47, 10.1038/nature16965 Raphael, 2017, Integrated genomic charatterization of pancreatic ductal adenocarcinoma, Cell, 32, 185 Drosos, 2017, Atm-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer, Sci Rep, 7, 11144, 10.1038/s41598-017-11661-8 An open-label phase Ib study of palbociclib (oral CDK 4/6 Inhibitor) plus abraxane (Registered) (Nab-Paclitaxel) in patients with metastatic pancreatic ductal adenocarcinoma. [Available online from: https://clinicaltrials.Gov/show/nct02501902] Phase I study of the CDK4/6 inhibitor palbociclib (PD-0332991) in combination with the PI3K/mTOR inhibitor gedatolisib (PF-05212384) for patients with advanced squamous cell lung, pancreatic, head & neck and other solid tumors. [Available online from: https://clinicaltrials.Gov/show/nct03065062] Shin, 2017, The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: a prospective cohort study, Oncotarget, 8, 17945, 10.18632/oncotarget.14901 Dreyer, 2017, Pancreatic cancer genomes: implications for clinical management and therapeutic development, Clin Cancer Res, 23, 1638, 10.1158/1078-0432.CCR-16-2411